NEW YORK (GenomeWeb News) – Microfluidic systems developer Fluxion Biosciences has received a Phase I grant from the National Institutes of Health to develop a platform for use in antimicrobial drug discovery and development programs, the company said today.
 
The San Francisco-based company did not disclose the amount of the grant and was not immediately available for comment.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.